The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to award a sole source, fixed-price maintenance agreement to Illumina, Inc. for a NextSeq 2000 sequencer, covering a base year plus four option years. The contract requires the contractor to provide OEM-certified parts, labor, travel, and technical support, including a 2-business-day on-site response target. Performance will take place at the NIAMS facility in Bethesda, Maryland, with deliverables due 30 days after service completion. The period of performance begins May 25, 2026, and extends through May 24, 2031, if all options are exercised. No budget amount is specified in the description.